Immunisation with bacterial expressed VP2 and VP5 of bluetongue virus (BTV) protect α/β interferon-receptor knock-out (IFNAR−/−) mice from homologous lethal challenge  by Mohd Jaafar, Fauziah et al.
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BTV-4  structural  proteins  VP2 (as two  domains:  VP2D1  and  VP2D2),  VP5  (lacking  the  ﬁrst  100  amino
acids:  VP51–100)  and  full-length  VP7,  expressed  in bacteria  as  soluble  glutathione  S-transferase  (GST)
fusion-proteins,  were  used  to immunise  Balb/c  and  /  interferon  receptor  knock-out  (IFNAR−/−)  mice.
Neutralising  antibody  (NAbs)  titres  (expressed  as log10 of the  reciprocal  of the  last  dilution  of mouse
serum  which  reduced  plaque  number  by  ≥50%)  induced  by the  VP2  domains  ranged  from  1.806  to 2.408
in  Balb/c  and  IFNAR−/− mice.
The immunised  IFNAR−/− mice  challenged  with  a homologous  live  BTV-4  survived  and  failed  to  develop
signs  of  infection  (ocular  discharge  and  apathy).  Although  subsequent  attempts  to  isolate  virus  were
unsuccessful  (possibly  reﬂecting  presence  of  neutralising  antibodies),  a  transient/low  level viraemia
was  detected  by  real  time  RT-PCR.  In contrast,  mice  immunised  with  the two  VP2 domains  with  or
without  VP51–100 and  VP7,  then  challenged  with  the  heterologous  serotype,  BTV-8,  all  died  by day  7
post-infection.
We  conclude  that  immunisation  with  bacterially-expressed  VP2  domains  can  induce  strong  serotype-
speciﬁc  NAb  responses.  Bacterial  expression  could  represent  a cost  effective  and risk-free  alternative  to
the use of live  or inactivated  vaccines,  particularly  if viruses  prove  to  be  difﬁcult  to  propagate  in cell  culture
(like BTV-25).  A  vaccine  based  on  bacterially  expressed  VP2  and  VP5  of  BTV  is  also  DIVA-compatible.
ublis©  2014  The  Authors.  P
. Introduction
Bluetongue virus is the type species of genus Orbivirus, family
eoviridae [1,2]. Bluetongue viruses (BTV) are transmitted by adult
ulicoides midges, causing ‘bluetongue’ (BT), a non-contagious but
conomically important disease of ruminants (sheep, cattle and
ome species of deer) [3,4]. Currently 26 BTV serotypes have been
dentiﬁed, 10 of which (BTV-1, 2, 4, 6, 8, 9, 11, 14, 16 and 25)
ave been detected in Europe since 1998 [5–7]. It is estimated
hat over one million sheep have died during repeated BT incur-
ions into the Mediterranean basin between 1998 and 2005 [5].
n outbreak caused by BTV-8 that started in the Netherlands dur-
ng 2006, subsequently spread across most of Europe, causing
igh levels of mortality in sheep (15–32%, reaching ∼50% is some
∗ Corresponding author. Tel.: +44 01483231194; fax: +44 01483 232448.
E-mail address: houssam.attoui@pirbright.ac.uk (H. Attoui).
ttp://dx.doi.org/10.1016/j.vaccine.2014.05.056
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
areas), as well as signiﬁcant clinical signs but low mortality (<1%)
in cattle [8–13]. However, inactivated-virus vaccines were used
successfully, leading to the rapid eradication of BTV-8 from the
region. These inactivated vaccines, which were made available for
serotypes 1, 2, 4 and 8 of BTV are thought to work primarily through
generation of a protective serotype-speciﬁc neutralising-antibody
response targeting the VP2 antigen [2,14–21].
The BTV particle is made of seven structural proteins (VP1–VP7)
[2,22,23]. VP2 represents a primary target for neutralising anti-
bodies [1,2,16,17] and determines virus serotype [24]. VP2 shows
22.4–73% aa sequence variation between BTV serotypes [24]. VP5
of BTV, the second most variable BTV protein (aa identity of 41–79%
between BTV serotypes [25,26]) enhances neutralising antibody
response to VP2 [1,2,14,27].Selected structural-proteins of BTV-4, including two domains
of VP2 (aa 63–471 and 555–956), VP5 (from which a coiled-coil
sequence [amino acids 1–100] was  deleted to improve solubil-
ity) and full-length VP7, were expressed in bacteria as soluble
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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usion-proteins with glutathione S-transferase (GST). We  report the
se of these proteins to immunise mice, generating neutralising-
ntibodies to the homologous BTV serotype.
. Materials and methods
.1. Cell lines, viruses and mice
KC cells (Culicoides variipennis) were grown at 28 ◦C in Schnei-
er’s Drosophila medium, supplemented with 10% foetal bovine
erum (FBS). BHK-21 cells (European Collection of Animal cell Cul-
ures: ECACC – 84100501), or BSR cells (a clone of BHK-21 a gift from
r. Noel Tordo, Institut Pasteur) were grown at 37 ◦C in Glasgow’s
inimum-Essential-Medium supplemented with 10% FBS.
BTV-4(SPA2003/01) was from blood of sheep showing severe
linical disease (Spain 2003). The virus was isolated in embryonated
ggs then adapted to BHK-21 cells (E1/BHK4). BTV-4(SPA2003/01)
as used for RNA extraction/cDNA synthesis for the purpose of
enerating protein expression constructs.
BTV-4-Italy03 and BTV-8-France-28 were isolated in embry-
nated eggs, from sheep-blood (Italy), or cow-blood (France),
hen adapted to BHK-21 cells (BTV-4-E1/BHK4 or BTV-8-E1/BHK2).
hese isolates were used for homologous and heterologous chal-
enge of IFNAR−/− mice.
Six weeks-old female Balb/cByJ mice were obtained from
harles River laboratories. Groups of six animals were immunised
ith proteins to assess NAb production.
Six weeks-old female IFNAR−/− mice (genetic background:
129SvEvBrd) were obtained from B&K Universal Ltd. Groups of
ix animals were used for immunisation with soluble expressed-
roteins followed by homologous or heterologous challenge with
ive BTV.
Immunisation protocols were approved by ethics committees at
he Pirbright Institute (license number 70/6133) and ANSES (license
umber 12/04/11-5).
.2. Construction of expression plasmids
Previous analysis has indicated that BTV-VP2 is potentially
ade of two related domains [18]. We  used BTV-4(SPA2003/01)
P2 domains which encompassed amino acid sequences 63–471
44.5 kDa) and 555–956 (46 kDa) (nucleotide positions: 187–1326
nd 1663–2868, Genbank accession: KJ700442).
VP5 lacked aa 1–100 (used sequence encompassed nucleotide
ositions 289–1581, Genbank accession: AJ783908) while the
ull-length aa sequence of VP7 was used (nucleotide pos-
tions: 1–1050, Genbank accession: KJ700443). All cDNAs were
loned into pGEX-4T-2 (expressing GST). The resulting plasmids
re pGEX-BTV4VP2D1, pGEX-BTV4VP2D2, pGEX-BTV4VP5 and
GEXBTV4VP7. Their sequences were conﬁrmed by comparison to
arental virus sequences. Theoretical sizes of the GST-fused pro-
eins are 70.5 kDa (VP2 domain 1), 72 kDa (VP2 domain 2), 73 kD
VP5 lacking aa 1–100) and 64.5 kDa for the VP7. The full-length
RFs of VP2, VP5 and VP7 were also cloned in the mammalian-
xpression plasmid pCIneo (pCIneo-BTV-4VP2, pCIneo-BTV-4VP5,
r pCIneo-BTV-4VP7).
.3. Protein expression and puriﬁcation
pGEX-BTV4VP2D1, pGEX-BTV4VP2D2, pGEX-BTV4VP5 and
GEXBTV4VP7 were used to transform C41 bacteria, known to
mprove solubility of expressed proteins [28]. Overnight bacte-
ial cultures were grown in 2XYT medium at 37 ◦C. On the day
f expression bacterial cultures were grown until OD600 reached
.6, then fusion-protein expression was induced by addition of
.5 mM IPTG and incubation of the cultures at 28 ◦C for 4 h with 32 (2014) 4059–4067
shaking at 200 rpm. Bacteria were pelleted (3250 g) and lysed by
sonication. Soluble proteins were puriﬁed from bacterial lysates by
glutathione-afﬁnity chromatography as previously described [29],
then analysed by sodium-dodecyl-sulphate (SDS) polyacrylamide
gel electrophoresis (PAGE). GST-fused proteins from inclusion bod-
ies (insoluble fraction) were dissolved in a CAPS buffer (CAPS
50 mM,  DTT 1 mM and Sarkosyl 0.3%), hence denaturing the pro-
teins [30]. The dissolved and denatured protein was dialyzed
overnight against 20 mM Tris–HCl pH 8.5. Insoluble proteins dis-
solved in CAPS buffer/dialysed are referred to as ‘CAPS-denatured
proteins’ throughout the text. Puriﬁed proteins were quantiﬁed by
two different methods: (i) a Bradford assay at 595 nm and (ii) UV
spectrophotometry at 280 nm (extinction coefﬁcient determined
from aa sequences of each fusion protein). Concentration mea-
surements were consistent using both methods. Relative amounts
of proteins to be injected were based on copy number consider-
ations in a BTV particle, as determined by X-ray crystallography
(780 copies for VP7, 360 copies for VP5 and 180 copies for VP2 [1]).
2.4. Immunisation of mice with soluble bacterial expressed
proteins
2.4.1. Immunisation of Balb/c
Seven groups of six Balb/c mice were injected subcutaneously
at days 0, 14 and 28 with 100 l of soluble protein/Montanide ISA
50V emulsion (Table 1).
Three groups of six Balb/c mice were injected subcutaneously
at days 0, 14 and 28 with 100 l of CAPS-denatured pro-
tein/Montanide ISA 50V emulsion (Table 1).
A group of six Balb/c mice were injected subcutaneously at days
0, 14 and 28 each with 100 l of Zulvac-4® Bovis. Sera were used
for normalisation of ELISA results.
A group of six control Balb/c mice which were not immunised
with any of the antigens was  also included.
2.4.2. Immunisation and challenge of IFNAR−/− mice
Six groups of six IFNAR−/− mice were injected subcutaneously at
days 0, 14 and 28 with: a mixture of VP2 domain 1 (VP2D1) and VP2
domain 2 (VP2D2) in Montanide, then challenged with (i) BTV-4 or
(ii) BTV-8; or a mixture of VP2D1 + VP2D2 + VP51–100/Montanide,
then challenged with (iii) BTV-4 or (iv) BTV-8; or a mixture
VP2D1 + VP2D2 + VP51–100 + VP7/Montanide, then challenged
with (v) BTV-4 or (vi) BTV-8 (Table 1). Blood samples were
collected at day 0 and day 28.
The mice received an intravenous lethal [31] challenge on
day 40, with 103 pfu of BTV-4-italy03 (homologous-challenge), or
10 pfu of BTV-8-28 (heterologous-challenge). Blood was collected
on the day of challenge (day 40), then at days 2, 3, 4, 5, 7, 10 and
12 p.i. Sera were tested for anti-VP2, anti-VP5 and anti-VP7 anti-
bodies by ELISA and immunoﬂuorescence and for NAbs by PRNT.
Two groups of six IFNAR−/− mice were injected subcutaneously
with VP51–100 on days 0, 14 and 28. These groups were not chal-
lenged with BTV-4 or BTV-8. Two  additional groups of six IFNAR−/−
mice were immunised with VP7 on days 0, 14 and 28, then chal-
lenged at day 40 with either BTV-4 or BTV-8.
Two groups of non-immunised mice were used as positive con-
trols, to conﬁrm lethality of BTV-4 or BTV-8 challenge-strains. Blood
from these two  groups was taken at days 0 and 40 (just before chal-
lenge) in order to assess reactivity of sera with BTV-4 ELISA and for
PRNT.
2.5. Detection of BTV-speciﬁc antibodies2.5.1. Western blot
Sera were analysed by western blotting using BTV-infected
cell-lysate antigens, as previously described [29,30,32]. Anti-VP2,
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Table  1
combinations of antigens used for immunisation (Balb/c or IFNAR−/− mice) and levels of antibodies in mouse sera against BTV-4 (by PRNT and ELISA).
Antigen form Antigen used in 1st,
2nd and 3rd injections
(amount of
antigen/animal)
Mouse strain
(number of
animals)
NA at day 40
(A)
Mean
antibody
titre ± SD (B)
Statistical
groups (C)
ELISA mean
NOD  ± SD (D)
Soluble proteins VP2D1 (15 g) Balb/c (6) 1/32–1/40 1.569 ± 0.06 C 0.68 ± 0.04
Soluble  proteins VP2D2 (15 g) Balb/c (6) 1/2–1/3 0.498± 0.05 D 0.59 ± 0.05
Soluble  proteins VP2D1 (15 g) + VP2D2
(15 g)
Balb/c (6) 1/64–1/128 2.007± 0.15 B 0.75 ± 0.05
Soluble  proteins VP2D1 (15 g) + VPD2
(15 g)+ VP51–100
(25 g)
Balb/c (6) 1/128–1/256 2.358 ± 0.12 A 0.78 ± 0.04
Soluble  proteins VP2D1 (15 g) + VPD2
(15 g)+ VP51–100
(25 g) + VP7 (40 g)
Balb/c (6) 1/128–1/256 2.258 ± 0.16 A 0.82 ± 0.06
Soluble  proteins VP51–100 (25 g) Balb/c (6) NNT N/A N/A 0.63 ± 0.04
Soluble  proteins VP7 (40 g) Balb/c (6) NNT N/A N/A 0.67 ± 0.04
Insoluble proteins (dissolved
in CAPS buffer)
VP2D1 (15 g) Balb/c (6) NNT N/A N/A 0.63 ± 0.05
Insoluble proteins (dissolved
in CAPS buffer)
VP2D2 (15 g) Balb/c (6) NNT N/A N/A 0.59 ± 0.04
Insoluble proteins (dissolved
in CAPS buffer)
VP2D1 (15 g) + VP2D2
(15 g)
Balb/c (6) NNT N/A N/A 0.73 ± 0.04
Zulvac®-4 Zulvac®-4 (100 l) Balb/c (6) 1/256–1/512 2.508 ± 0.15
None None Balb/c (6) NNT N/A N/A 0.05 ± 0.02
Soluble  proteins VP2D1 (15 g) + VP2D2
(15 g)
IFNAR−/− (12) 1–64-1/128 2.007 ± 0.15 B 0.73 ± 0.0
Soluble  proteins VP2D1 (15 g) + VPD2
(15 g) + VP51–100
(25 g)
IFNAR−/− (12) 1/128–1/256 2.333 ± 0.14 A 0.78 ± 0.05
Soluble  proteins VP2D1 (15 g) + VPD2
(15 g)+ VP51–100
(25 g) + VP7 (40 g)
IFNAR−/− (12) 1/128–1/256 2.257 ± 0.16 A 0.82 ± 0.05
Soluble  proteins VP51–100 (25 g) IFNAR−/− (12) NNT N/A N/A 0.58 ± 0.04
Soluble  proteins VP7 (40 g) IFNAR−/− (12) NNT N/A N/A 0.61 ± 0.06
None  None IFNAR−/− (12) NNT N/A N/A 0.04 ± 0.02
A: minimum and maximum dilutions of mice sera (per group of mice) collected at day 40 (12 days after receiving the third dose of antigen) which reduced the BTV-4 plaque
number by ≥50%.
B: mean value of the log10 (±standard deviation: SD) of the reciprocal of the last dilution of mouse serum which reduced BTV-4 plaque numbers by ≥50%.
C:  statistical information for groups of mice obtained using Tukey’s method, 95.0% conﬁdence. Mean antibody titres (shown in B) which do not share a letter are signiﬁcantly
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:  ELISA was conducted using heat inactivated BTV-4 only (not BTV-8).
/A: not applicable; NNT: no neutralisation.
nti-VP5 or anti-VP7 antibodies were diluted at 1/50, while
nti-mouse peroxidase-conjugated antibody was diluted at
/750.
.5.2. ELISA
Supernatant of BTV-4-infected BHK-21 cells was clariﬁed by
entrifugation at 3000 × g, then inactivated at 56 ◦C for 1 h. The
nactivated BTV-4 virus suspension was mixed volume to vol-
me  with 100 mM sodium carbonate buffer pH 9.6 and 100 l
as used to coat 96 well plates (4 ◦C for 16 h). Sera were diluted
/100 in 5% skim-milk and ELISA were conducted as previously
escribed [29,30,32]. A serum sample from Balb/c mice immunised
ith Zulvac-4®-Bovis (inactivated BTV-4, Zoetis) was identiﬁed as
he ‘standard’ against which all OD readings were subsequently
ormalised. Normalised optical density (NOD) was  calculated as
OD = [OD (sample) − OD (Blank reaction)]/[OD (standard) − OD
Blank reaction)]. An ELISA based on clariﬁed supernatants from
on-infected cells was also used.
.5.3. Immunoﬂuorescence
BSR cells were grown on coverslips in 24-well plates, transfected
ith pCIneo-BTV-4VP2, pCIneo-BTV-4VP5, or pCIneo-BTV-4VP7
nd processed for immunoﬂuorescence as previously described
22]. Cells were probed with anti-VP2, anti-VP5 or anti-VP7 anti-
odies diluted 1/500 in phosphate-buffered saline containing 0.5%
ovine serum albumin.2.5.4. Plaque-reduction neutralisation-tests (PRNT) and plaque
assay
BSR cells were plated (1 × 105 cells/well) in 48 well plates a day
before PRNT initiated [33]. 50 pfu of BTV-4 or BTV-8, in 125 l of
Eagle’s minimum essential medium (EMEM), were incubated with
125 l of two-fold serial dilutions of mouse sera in EMEM,  incu-
bated at 37 ◦C for 2 h, then added to conﬂuent BSR cell-monolayers.
The supernatant was  discarded and replaced with molten 1% low
melting point agarose (Sigma) in EMEM.  Plates were subsequently
incubated at 37 ◦C for 5 days, ﬁxed by addition of 2 ml  of 10%
formaldehyde in phosphate-buffered saline per well. After removal
of agarose plugs, monoloayers were stained with 0.1% naphthalene-
black solution, then washed with deionised water and plaques
counted.
For plaque assay, the number of plaque-forming units (PFU) was
determined using the same approach, while omitting the use of
mouse serum.
2.6. RNA extraction and real-time PCR
BTV-4(SPA2003/01) infected BHK-21 cells were harvested at day
4 post-infection. Cells were centrifuged at 2000 × g and pellets were
extracted with ‘RNA Now’ (Biogentex) [34].Blood from challenged IFNAR−/− mice was extracted using
‘RNA Now’ as previously described [35,36]. This extraction method
results in high sensitivity for viral RNA detection in mouse blood
[36].
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Supernatants from BTV-4 or BTV-8 infected cell-cultures were
lariﬁed at 2000 × g, concentrated 10-fold using Vivaspin® concen-
rators (MWCO  100K) then treated with RNase-A and benzonase to
emove non-encapsidated nucleic acids. Ten-fold serial dilutions
f the concentrated virus were prepared in serum-free GMEM,  for
itration in triplicate by PRNT (as described above).
A dilution series of concentrated supernatant was  also prepared
n GMEM and added to non-infected mouse blood, then extracted
ith ‘RNA Now’, to determine the correlation between PFU and
eal-time RT-PCR ‘cycle threshold’ (Ct) values (to allow estimates
f PFU-equivalents, only when BTV RNA was detected by RT-PCR
ut no virus could be isolated from blood samples).
The presence of viraemia was ‘assessed’ by BTV serogroup-
peciﬁc real-time RT-PCR targeting Seg-1 [37] and virus isolation
n BSR and KC cells.
.7. Statistical analyses
Analysis of variance (ANOVA) between groups of mice, was
arried out using Minitab-16 software (Minitab Inc., UK), or the
ystat-5.03 program (Systat Inc., Evanston, IL). Statistical signiﬁ-
ance between groups was assessed by a general linear model using
ukey’s test (differences are considered as statistically signiﬁcant
hen P < 0.05).
. Results
.1. Expression VP2 domains, VP5 and VP7
Expression of GST-fused domains VP2D1 (aa 63–471) and
P2D2 (aa 555–955) in C41 bacteria at 28 ◦C enhanced their solubil-
ty (∼30% soluble proteins) (Fig. 1A). The yields of soluble GST-fused
P2 domains were similar batch to batch at ∼0.5 mg/ml  (1 ml  of
rotein from 100 ml  of bacterial culture).
Deletion of aa 1–100, which forms part of the coiled-coils NH2-
erminal structure (VP51–100) dramatically increased solubility
Fig. 1B) (∼60% soluble protein), yielding 1.5 mg/ml of protein (1 ml
f protein from 100 ml  of bacterial culture). Deletion of residues
eyond aa 100 caused no further improvement in solubility.
The expressed BTV-4-VP7(T13)/GST-fusion protein was soluble
Fig. 1C) at a concentration of ∼1 mg/ml  (1 ml  of protein from 100 ml
f bacterial culture).
.2. Relating cycle-threshold (Ct) values to PFU-equivalents of
TV-4 or BTV-8
Standard curves were generated to compare Ct values from real-
ime RT-PCR assays, with virus titres (PFU/ml) for BTV-4 and BTV-8
reparations. Both curves show a high correlation (R2 values of
.988 and 0.997 respectively). The number of PFU-equivalents for
TV-4 or BTV-8 in mouse blood can be calculated from the for-
ulas y = −1.667ln(x) + 37.874 (BTV-4) or y = −1.772ln(x) + 38.082
BTV-8), where y is the Ct value determined by real time PCR assay
nd x is the number of PFU-equivalents/ml. The value of x will be
 = e(y−37.874)/(−1.667) for BTV-4, or x = e(y−38.082)/(−1.772) for BTV-8,
here e = 2.71828 is the base of natural logarithm. Results were
onsistent when BTV-4 or BTV-8 were grown in different batches
f BSR cells. Otherwise, number of PFU was determined by virus
solation on BSR cells.
.3. Immunisation of mice, PRNT and ELISA.3.1. Immunisation of Balb/c
CAPS-denatured BTV-4 VP2 domain 1 and 2/GST-fusion proteins
aised antibodies which detected a ∼110 kDa protein (corre-
ponding to VP2) in a BTV-4(SPA2003/01) infected-cell lysate, by 32 (2014) 4059–4067
Western-blotting (Fig. 1d). They also detected inactivated BTV anti-
gen in ELISA (Table 1), but failed to neutralise BTV-4(SPA2003/01).
Soluble BTV-4 VP2 domain 1 and 2/GST-fusion proteins,
VP51–100 and VP7, all raised antibodies that gave positive results
using inactivated BTV-4 ELISA (Table 1). These antibodies also
detected bands of the predicted size for VP2 (∼110 kDa), VP5
(∼60 kDa) and VP7 (∼38 kDa) in BTV-4(SPA2003/01) infected cell
lysates by western-blotting (Fig. 1e, f, g). In contrast to expressed
proteins that had been ‘CAPS-denatured’, antisera against the sol-
uble amino terminal domain of VP2 contained NAbs with titres
of 1.505–1.602 (Table 1), giving ≥50% plaque reduction. Lower
titres of neutralising antibodies (0.301–0.477, P < 0.05) were found
in antisera against the carboxy-terminal domain. Sera from mice
immunised with: VP2D1 + VP2D2; VP2D1 + VP2D2 + VP51−100; or
VP2D1 + VP2D2 + VP51−100 + VP7, all neutralised the homologous
BTV-4(SPA2003/01) at higher titres (1.806–2.408) but (as expected)
failed to neutralise BTV-8 (Table 1).
Neutralising antibody titres generated by Balb/c mice immu-
nised with VP2D1 + VP2D2 + VP51–100 or VP2D1 + VP2D2 +
VP51–100 + VP7 were not signiﬁcantly different, but were signiﬁ-
cantly higher (P < 0.05) than those immunised with VP2D1 + VP2D2
(Table 1).
3.3.2. Immunisation of IFNAR−/−
Neutralising antibody (NAb) titres of 1.806–2.017 were detected
in mice immunised with VP2D1 + VP2D2; with 2.017–2.408 in those
immunised with VP2D1 + VP2D2 + VP51–100 or VP2D1 + VP2D2 +
VP51–100 + VP7 (Table 1), supporting previous studies indicating
that VP5 may  play a signiﬁcant role in generation of NAbs [38–40].
There was  no statistical difference between immunisation with
VP2D1 + VP2D2 + VP51–100, or VP2D1 + VP2D2 + VP51–100 + VP7,
but a signiﬁcant difference compared to immunisation with
VP2D1 + VP2D2 only (P < 0.05) (Table 1).
Sera from IFNAR−/− mice immunised with recombinant
VP2D1 + VP2D2, VP51–100 and VP7, ether singly or in different
combinations, all reacted with BTV-4 by ELISA (Table 1). The speci-
ﬁcity of the antibodies was  also conﬁrmed by immunoﬂuorescence
(supplementary ﬁgure).
Sera from non-immunised mice did not neutralise BTV-4 nor
show cross reactivity with BTV-4 ELISA.
3.4. Challenge of IFNAR−/− mice and viraemia
Mouse survival times p.i. provide a relative measure of protec-
tion afforded by vaccination.
Blood samples collected on days 2, 3, 4, 5, 7, 10 and 12 p.i., and
tested.
3.4.1. Immunised IFNAR−/− challenged with BTV-4
Mice immunised with VP2D1 + VP2D2, VP2D1 + VP2D2 +
VP51–100 or VP2D1 + VP2D2 + VP51–100 + VP7, then challenged
with BTV-4, all survived until the end of the experiment on day 52
(12 days p.i.) (Fig. 2A). Two mice immunised with VP2D1 + VP2D2
were positive (Ct value of 34) on day 4 p.i. with BTV-4. Because no
virus could be isolated from blood on KC cells or by plaque assay
using BSR cells (possibly reﬂecting the presence of neutralising
antibodies), we calculated PFU-equivalents using the formula
linking Ct values to PFU numbers. A low PFU-equivalents/ml was
calculated (∼0.3–9). Two mice in each group immunised with
VP2D1 + VP2D2 + VP51–100, or VP2D1 + VP2D2 + VP51–100 + VP7,
were also potentially viraemic on day 5 p.i. (Ct values ∼39),
although no virus could be isolated on KC cells or by plaque
assay on BSR cells (Fig. 2B). None of the animals in groups immu-
nised with VP2D1 + VP2D2 showed any signs of infection (ocular
discharge and apathy [31]) post-challenge with BTV-4 and no
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Fig. 1. VP2D1, VP2D2, VP51–100 and VP7 expression in bacteria and western blots using BTV-4 infected BSR cell lysates as antigens. (A–C) Bacterial expression of recombinant
proteins. Gels were stained with Coomassie blue. Proteins were expressed in C41 bacteria, puriﬁed by glutathione-afﬁnity chromatography and analysed by SDS-PAGE. (A)
Soluble  VP2 domains 1 (GST-VP2D1) and 2 (GST-VP2D2) fused to GST. (B) Soluble GST-VP51–100. (C) Soluble full-length GST-VP7. (D–G) Western blots using Balb/c mouse
antibodies generated against the recombinant proteins VP2D1 + VP2D2, VP51–100 or VP7 tested with BTV-4-infected cell lysates. Lane M: size marker labelled in kDa. The
position of the protein band revealed by western blot is indicated by an arrow. (D) Antibodies against VP2D1 and VP2D2 from inclusion bodies (insoluble proteins dissolved
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in  CAPS buffer prior to immunisation). (E) Antibodies to mixtures of soluble VP2
ells.  (F) Antibodies to VP51–100 tested against lysates of BTV-4-infected (INF) or n
TV-4-infected (INF) or non-infected (N-INF) BSR cells.
iraemia was detected by RT-PCR after day 7 p.i. All animals
urvived to the end of the experiment (Table 2, Fig. 2A).
.4.2. Immunised IFNAR−/− challenged with BTV-8
Mice immunised with VP2D1 + VP2D2, or VP2D1 + VP2D2 +
P51–100 of BTV-4, but challenged with BTV-8, showed signs of
nfection by day 3 p.i., and all had died by day 5 p.i (Fig. 2C). Ct val-
es of 20.7–22.4, and virus titres calculated by plaque assay were
 × 103–2 × 104 pfu/ml on day 4 p.i. In contrast, time of death was
elayed (day 5–7 p.i. [P < 0.05]) by addition of VP7 to this immun-
sation regime (BTV-4 VP2D1 + VP2D2 + VP51–100 + VP7) (Fig. 2C),P2D2 tested against lysates of BTV-4-infected (INF) or non-infected (N-INF) BSR
fected (N-INF) BSR cells. (G) Antibodies to full-length VP7 tested against lysates of
with Ct values on day 5 p.i. of 22.4–23.7 (virus titres calculated by
plaque assay: 3 × 103–7 × 103 pfu/ml, Fig. 2D).
3.4.3. Controls
The two non-immunised control-groups, challenged with BTV-
4(italy03), or BTV-8(BTV-8-28) were all positive by RT-PCR on day 3
p.i. and all died by day 5 p.i. (Fig. 2A and C) with Ct values 20.9–22.7.
Virus was successfully isolated from these animals on both KC cells
and BSR (BSR plaque assay titres: 5 × 103–3 × 104 pfu/ml (Fig. 2B
and D)).
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Fig. 2. Survival of IFNAR−/− mice challenged with BTV-4 or BTV-8 and virus titres expressed as log10 plaque forming units (PFUs were determined by plaque assay in BSR cells).
Groups of IFNAR−/− mice included non-immunised mice and mice immunised with VP2D1 + VP2D2, VP2D1 + VP2D2 + VP51–100, or with VP2D1 + VP2D2 + VP51–100 + VP7.
(A)  Mice in the non-immunised group challenged with BTV-4 died by day 5 post-challenge while immunised animals were protected and all animals survived until the end of
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the  experiment. (B) Virus titres (PFU as determined by plaque assay in BSR cells) in t
nimals survived until the end of the experiment and no virus was isolated by cell c
D)  Virus titres (PFU as determined by plaque assay in BSR cells) in the groups of no
Animals in the group immunised with VP51–100 were not chal-
enged because initial studies with Balb/c mice showed that sera
f mice immunised with VP51–100 only, did not neutralise virus
nfectivity.
All animals in the groups immunised with VP7 only, died
y day 5 p.i. with levels of BTV-speciﬁc RNA in blood similar
o non-immunised mice (BSR plaque assay titres: 4 × 103–2.7 ×
04 pfu/ml). This suggests that increased survival times of mice
mmunised with VP2D1 + VP2D2 + VP51–100 + VP7 is not due to
P7 alone, but may  be an effect of combining these different pro-
eins.
. Discussion
Several inactivated mono- and multivalent vaccines for BTV
erotypes 1, 2, 4 or 8, have been authorised via the European
edicines Agency for use in ruminants, particularly cattle and
heep [41,42]. These relatively un-puriﬁed vaccine antigens raise
ntibodies to all virus structural and non-structural proteins, mak-
ng it impossible to distinguish infected from vaccinated animals
DIVA) by serological assays.
Previous studies exploring recombinant-expressed BTV struc-
ural proteins as subunit-vaccine candidates have evaluated crude
ysates of recombinant-baculovirus-infected insect cells express-
ng BTV VP2 and VP5 [43–45]. Immunisation of sheep with these
roteins, protected the animals and raised signiﬁcant NAb titres
up to 2.408), with transient or undetectable viraemia after a sub-
equent homologous-BTV challenge [43]. Recently, it was shown
hat baculovirus-expressed and puriﬁed VP2 induced neutralisingups of non-immunised and immunised groups challenged with BTV-4. Immunised
. (C) Groups of IFNAR−/− challenged with BTV-8 all died by day 5–7 post challenge.
unised and immunised groups challenged with BTV-8.
antibodies [45] and is stable at +4 ◦C as well as −80 ◦C for almost 2
years [46]. Immunisation with virus-like particles (VLPs) contain-
ing capsid-proteins (VP3, VP7, VP2 and VP5) also protected sheep
and raised NAbs (titres of upto 2.107) generating sterile immunity
post-homologous-challenge [44]. However, VLPs are thought to be
relatively unstable and have a limited shelf life.
Other experimental subunit-vaccines for BTV include vectored-
virus vaccines such as modiﬁed vaccinia Ankara (MVA), capripox
virus, canarypox virus, bovine herpes virus, equine herpesvirus or
myxomavirus [43,44,47–54]. However, simple bacterial expression
systems have not been fully explored, due to difﬁculties generating
larger BTV proteins (such as VP2 ∼112 kDa) in a native and soluble
form for use as subunit-vaccine antigens [55].
Previous ﬁndings suggested that VP2 of BTV (∼110 kDa), evolved
through duplication and may  therefore exist as two related
domains, VP2D1 and VP2D2 [18]. Sera from Balb/c mice immu-
nised with the soluble recombinant VP2D1 of BTV-4, neutralised
the homologous virus, while signiﬁcantly lower NAb titres were
observed with sera of mice immunised with soluble VP2D2. This
suggests that the majority of the dominant neutralising epitopes
are located in the amino terminal half of VP2. However, when both
domains were mixed together on an equimolar basis, higher titres
of neutralising antibodies were elicited. There is published evi-
dence that neutralisation epitopes are located in the ﬁrst ∼350
amino acids (domain 1) of VP2 of BTV-10 [56]. IFNAR−/− mice
immunised with VP2D1 + VP2D2 and challenged with live BTV-4
survived until the end of the experiment with a transient viraemia
(∼0.3–9 pfu/ml detected by RT-PCR only) which was  cleared sub-
sequently. It was  not possible to isolate virus in cell cultures from
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Table  2
Detection of BTV-4 or BTV-8 RNA in blood samples from IFNAR−/− mice post-challenge.
Group number Mouse Ct Day 2 Ct Day 3 Ct Day 4 Ct Day 5 Ct Day 7 Ct Day 10 Ct Day 12
Group 1
Immunogen: VP2D1 + VP2D2
Challenge virus: BTV-4
1 Neg Neg Neg Neg Neg Neg Neg
2  Neg Neg 34.1 Neg Neg Neg Neg
3  Neg Neg Neg Neg Neg Neg Neg
4  Neg Neg Neg Neg Neg Neg Neg
5  Neg Neg 34.5 Neg Neg Neg Neg
6  Neg Neg Neg Neg Neg Neg Neg
Group  2
Immunogen: VP2D1 + VP2D2 + VP5
Challenge virus: BTV-4
1 Neg Neg Neg Neg Neg Neg Neg
2  Neg Neg Neg 39.7 42.3 Neg Neg
3  Neg Neg Neg Neg Neg Neg Neg
4  Neg Neg Neg 40.6 42.9 Neg Neg
5  Neg Neg Neg Neg Neg Neg Neg
6  Neg Neg Neg Neg Neg Neg Neg
Group  3
Immunogen: VP2D1 + VP2D2 + VP5 + VP7
Challenge virus: BTV-4
1 Neg Neg Neg 38.7 Neg Neg Neg
2  Neg Neg Neg Neg Neg Neg Neg
3  Neg Neg Neg Neg Neg Neg Neg
4  Neg Neg Neg 39.1 Neg Neg Neg
5  Neg Neg Neg Neg Neg Neg Neg
6  Neg Neg Neg Neg Neg Neg Neg
Group  4
Immunogen: VP2D1 + VP2D2
Challenge virus: BTV-8
1 39.1 28.8 20.8 D
2  36.5 27.1 22.4 D
3  35.8 27.6 D
4  37.4 28.2 21.5 D
5  39.9 26.5 21.8 D
6  34.1 26.3 D
Group 5
Immunogen: VP2D1 + VP2D2 + VP5
Challenge virus: BTV-8
1 34.9 29.5 20.7 D
2  36.8 28.9 D
3  38.4 30.1 21.4 D
4  34.3 28.5 D
5  34.7 29.6 D
6  38.6 30.3 21.6 D
Group  6
Immunogen: VP2D1 + VP2D2 + VP5 + VP7
Challenge virus: BTV-8
1 41.3 34.8 29.5 22.4 D(day6)
2  42.4 33.6 28.4 D
3  40.1 35.1 30.2 D
4  39.3 34.5 31.8 23.7 D
5  41.6 35.4 28.7 D
6  Neg 33.8 30.7 22.6 D
Group  7 (BTV-4 Control)
Immunogen: none
Challenge virus: BTV-4
1 36.3 26.7 21.4 D
2  37.1 27.2 D
3  35.7 26.1 20.9 D
4  34.6 28.3 D
5  35.1 25.9 D
6  34.7 28.5 D
Group 8 (BTV-8 Control)
Immunogen: none
Challenge virus: BTV-8
1 37.6 29.1 D
2  36.9 28.7 D
3  38.1 28.5 D
4  35.3 27.9 22.7 D
5  34.8 28.1 21.6 D
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NA was  extracted from mouse blood samples and tested using a generic BTV Seg-1
hese blood samples, potentially reﬂecting presence of neutralising
ntibodies.
The CAPS-denatured (from insoluble fraction) VP2 domains did
ot raise any neutralising antibody response as compared to the
oluble domains in bacteria. This strongly suggests that at least
ome neutralisation epitopes are conformational, which have been
ost by dissolving the insoluble VP2 domains in a detergent such
s CAPS. Several studies identiﬁed linear epitopes in VP2 which are
erotype speciﬁc, some of which when used in the form of peptides
revented virus neutralisation [57–59].
Although BTV-VP2 is the primary determinant of serotype,
he smaller outer capsid protein VP5, stimulates the neutralisa-
ion response, possibly through interactions with VP2 in the virus
apsid [14,15]. Mice vaccinated with a combination of expressed
P51–100 and VP2 domains of BTV-4, generated higher neu-
ralising antibody titres (P < 0.05) (against BTV-4, but not BTV-8)D
time PCR assay. D: animal died.
and delayed the transient viraemia (detected by RT-PCR, while
no virus could be isolated by KC or BSR cell cultures) observed
in some animals after homologous challenge than mice vacci-
nated with VP2 domains alone. However, addition of VP5 did not
have signiﬁcant differences in terms of protection. The absence
of neutralisation of BTV-8 is an indication that the neutral-
ising antibodies elicited by BTV-4 VP2 domains are serotype-
speciﬁc.
VP7(T13) is an immuno-dominant orbivirus-species/serogroup-
speciﬁc antigen [51,60,61]. Antibodies to VP7 can neutralise the
infectivity of BTV core-particles, but do not signiﬁcantly neutralise
intact virus particles [62]. The incorporation of baculovirus-
expressed VP7 in previously reported vaccination studies using
VP2 and VP5, also failed to enhance NAb responses in sheep [43].
However, vaccination with BTV-VP7 has been shown to induce
a partially-protective cytotoxic T-cell response that may  reduce
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iraemia [63]. Capripoxvirus expressing VP7 was shown to confer
ross-protection [51].
Although vaccination with baculovirus-expressed BTV core-
ike-particles (CLP – containing VP3 and VP7) did not prevent
linical signs of the disease, it did reduce their severity [44].
The addition of expressed VP7 to vaccination antigens (with
P51–100 and soluble domains of VP2) failed to increase neutral-
sing antibody titres (against BTV-4) and failed to protect IFNAR−/−
ice from lethal challenge with BTV-8. Regardless of the antigen
ombination which we used, there was no protection from the
eterologous BTV-8 lethal challenge. These results show that the
esponse to immunisations is serotype-speciﬁc and that VP2 is the
ain protective component in the three combinations of antigens.
The results presented show that soluble BTV-VP2 domains and
P5 can be expressed in bacteria, suggesting that they adopt a
ative conformation/fold in this system.
The aim of this study was to assess bacterially-derived BTV
tructural-proteins as candidates for a DIVA-compatible subunit-
accination-strategy, using Balb/c mice and the well-established
TV animal-model, IFNAR−/− mice. DIVA-compatible BTV vaccines
ould be based on a subset of the viral proteins, with detection
f antibodies to the remaining protein(s) as surveillance mark-
rs for previous infections. Our results demonstrate potential for
 bacterial-expressed BTV-subunit DIVA vaccine, based principally
n VP2 and VP5. The exclusion of VP7, which does not seem to
nﬂuence protection, provides a mean for DIVA.
The two expressed VP2 domains, VP2D1 and VP2D2 combined
n equimolar basis, generated high titres of neutralising antibodies
ith similar titres in both Balb/c and IFNAR−/−. Although a transient
iraemia was observed in mice immunised with VP2D1 + VP2D2,
ost-challenge with BTV-4, this was rapidly cleared and they sur-
ived without signs of infection throughout the experiment. This
ndicates that soluble bacterial-expressed antigens are protective
nd do not require more complex eukaryotic expression systems.
The use of bacterial-expressed protein antigens, could provide
 safe and scalable alternative to live-attenuated BTV vaccines.
acterial expression could represent an alternative to inactivated
accines, particularly if viruses prove to be difﬁcult to propagate
n cell culture (like BTV-25 [7]). These antigens could be used in
ifferent combinations (from multiple-serotypes) or with ‘virus-
ectored’ and/or DNA vaccines to create cross-serotype, or stronger
rotective responses.
The ability of bacterially-expressed BTV subunit-vaccines to
nduce NAbs and protect sheep and cattle (natural hosts of BTV)
ill require further validation.
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